People · Operator
Named in public records as an officer, director or promoter · active 2008–2024 · Other, Biotechnology, Other Health Care, Healthtech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Chromatin, Inc. | — | Other | Series B | $61.3M | $228.4M | 2011 |
| Juventas Therapeutics Inc | — | Biotechnology | Series B | $35.8M | $52.0M | 2008 |
| BlueWillow Biologics, Inc. | — | Biotechnology | Series A | $35.0M | $5.5M | 2018 |
| Celleration Inc | — | Other Health Care | Series A | $14.4M | $129.7M | 2011 |
| POPS! Diabetes Care, Inc. | — | Healthtech | Series A | $9.7M | $133.6M | 2018 |
| NERITES Corp | — | Other Health Care | Seed | $2.3M | $14.9M | 2009 |
George Arida at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside George Arida on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| George Emont | 2 | 4 |
| Somu Subramaniam | 1 | 17 |
| Robert Shapiro | 1 | 13 |
| Mark Wagner | 1 | 9 |
| John Hamer | 1 | 7 |
| Peter Shagory | 1 | 5 |
| Linda Tufts | 1 | 5 |
| Roger Newton | 1 | 4 |
| Norman C. Selby | 1 | 4 |
| Daniel Davis | 1 | 4 |
| Marc Penn | 1 | 4 |
| Kevin Etzkorn | 1 | 3 |
| Christopher Geyen | 1 | 3 |
| Rahul Aras | 1 | 3 |
| Nancy Ness | 1 | 3 |
| Suzette Dutch | 1 | 3 |
| David Woodburn | 1 | 3 |
| Meghan Sharp | 1 | 3 |
| Troy Ignelzi | 1 | 3 |
| Walter Dewey | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.